XBIOTECH INC.: 10-Q filed 2025-11-12
What XBIOTECH INC. reported in its quarterly report filed 2025-11-12 (fiscal Q3 2025): 32 published measures, 90 facts as tagged in accession 0001171843-25-007233.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2025-11-12
- Fiscal period
- fiscal Q3 2025
- Accession
- 0001171843-25-007233 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All XBIOTECH INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 172,424,000 | USD | |
| At 2024-12-31 | 199,093,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 5,344,000 | USD | |
| At 2024-12-31 | 16,825,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 167,080,000 | USD | |
| At 2025-06-30 | 173,064,000 | USD | |
| At 2024-12-31 | 182,268,000 | USD | |
| At 2024-09-30 | 192,115,000 | USD | |
| At 2024-06-30 | 196,701,000 | USD | |
| At 2023-12-31 | 218,846,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 147,367,000 | USD | |
| At 2024-12-31 | 172,677,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -6,008,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -18,648,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -5,015,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -28,023,000 | USD | 274 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | -16,968,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | -24,423,000 | USD | 274 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 255,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 1,220,000 | USD | 274 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | -10,250,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 10,167,000 | USD | 274 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | -255,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | -1,220,000 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | -109,485,000 | USD | |
| At 2024-12-31 | -90,837,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 30,487,731 | shares | 92 |
| 2025-01-01 to 2025-09-30 | 30,487,731 | shares | 273 |
| 2024-07-01 to 2024-09-30 | 30,472,557 | shares | 92 |
| 2024-01-01 to 2024-09-30 | 30,459,178 | shares | 274 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -0.2 | USD/shares | 92 |
| 2025-01-01 to 2025-09-30 | -0.61 | USD/shares | 273 |
| 2024-07-01 to 2024-09-30 | -0.16 | USD/shares | 92 |
| 2024-01-01 to 2024-09-30 | -0.92 | USD/shares | 274 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 102,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 159,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 9,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 9,000 | USD | 274 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 23,473,000 | USD | |
| At 2024-12-31 | 24,526,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 3,460,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 1,125,000 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -6,047,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -25,930,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -7,904,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -33,723,000 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 148,951,000 | USD | |
| At 2024-12-31 | 174,567,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 3,565,000 | USD | |
| At 2024-12-31 | 15,105,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 1,043,000 | USD | |
| At 2024-12-31 | 2,223,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 450,000 | USD | |
| At 2024-12-31 | 700,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 6,047,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 25,930,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 7,904,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 33,723,000 | USD | 274 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 5,080,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 22,032,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 7,127,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 29,936,000 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 30,487,731 | shares | |
| At 2024-12-31 | 30,487,731 | shares |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 2,422,000 | USD | |
| At 2024-12-31 | 2,632,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 1,059,000 | USD | |
| At 2024-12-31 | 1,032,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -5,906,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -18,489,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -5,006,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -28,014,000 | USD | 274 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 967,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 3,898,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 777,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 3,787,000 | USD | 274 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 1,308,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 1,306,000 | USD | 274 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -85,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 906,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 25,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 25,000 | USD | 274 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 141,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 7,441,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 2,898,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 5,709,000 | USD | 274 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 486,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 400,000 | USD | 274 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | -1,180,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | -1,017,000 | USD | 274 |
Inspect the source
- Entity
- XBIOTECH INC. / CIK 0001626878
- Captured
- 2026-09-21T17:21:01.627Z
- SEC response SHA-256
a6de11d2b8459cb01d6a091b52bdf85e4210871e91aeae1935f184db69bac658
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001626878.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))